Plus Therapeutics' CNSide Diagnostics to expand in Texas starting August 2025.

Plus Therapeutics, a clinical-stage pharmaceutical company, announces its subsidiary CNSide Diagnostics will make its cerebrospinal fluid assay platform and testing services commercially available in Texas in August 2025. Initial focus will be on NCI-Designated Cancer Centers and large private healthcare systems. The company will expand testing services and broaden regional availability over the next 12 months.

Houston, TX — Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company specializing in targeted radiotherapeutics for central nervous system (CNS) cancers, has announced that its subsidiary, CNSide Diagnostics, LLC, will make its cerebrospinal fluid (CSF) assay platform and testing services commercially available in Texas starting in August 2025. The initial commercial focus will be on National Cancer Institute (NCI) Designated Cancer Centers and large private healthcare systems.

CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics, develops and commercializes proprietary laboratory-developed tests designed to identify tumor cells that have metastasized to the CNS. The CNSide CSF Assay Platform enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA in the cerebrospinal fluid, aiding in the management of patients with leptomeningeal metastases (LM).

The CNSide diagnostic tool has demonstrated significant clinical utility, with a sensitivity of 92% and specificity of 95%, and has influenced treatment decisions in over 90% of cases. Over 11,000 CNSide tests have been performed at over 200 U.S. cancer institutions since 2020 [1].

The company will initially target NCI-Designated Cancer Centers such as the University of Texas - Southwestern, MD Anderson Cancer Center, Mays Cancer Center, Baylor Scott & White Health, and Texas Oncology. Over the next 12 months, Plus Therapeutics plans to expand testing services and broaden regional availability [2].

About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the CNS. The company combines image-guided local beta radiation and targeted drug delivery approaches to advance its pipeline of product candidates, with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM).

References
[1] https://www.globenewswire.com/news-release/2025/07/31/3124879/0/en/Plus-Therapeutics-Provides-US-Launch-Update-for-its-CNSide-Diagnostic.html
[2] https://www.stocktitan.net/news/PSTV/plus-therapeutics-provides-us-launch-update-for-its-cn-side-n5ppjl4jo2cu.html